Pathogenesis and anti-proliferation mechanisms of Crocin in human gastric carcinoma cells.

Crocin IPA Nrf2 gastric cancer oxidative stress

Journal

International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565

Informations de publication

Date de publication:
2020
Historique:
received: 14 12 2019
accepted: 19 01 2020
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 9 6 2020
Statut: epublish

Résumé

Gastric cancer is the fourth most common cause of cancer death globally and the second most common in Asia. Many studies suggest that Crocin has the potential for gastric cancer antineoplastic combined chemotherapy protocols. Here we investigated genomic changes related to the inhibitory effect of Crocin, and elucidated the molecular mechanism of this inhibition in gastric carcinoma cells. We found that, compared with the control group, 216 significantly upregulated and 301 significantly downregulated genes were identified in Crocin-treated AGS cells. Many of these differentially expressed genes in AGS cells are involved in Nrf2-mediated oxidative stress response, p53 signaling, and integrin signaling, which suggested the mechanism of Crocin functions in therapy of gastric cancer. In summary, our study indicates that Crocin has the potential for gastric cancer adjuvant treatment through reducing cell oxidative stress levels.

Identifiants

pubmed: 32509062
pmc: PMC7270694

Types de publication

Journal Article

Langues

eng

Pagination

912-922

Informations de copyright

IJCEP Copyright © 2020.

Déclaration de conflit d'intérêts

None.

Références

Chem Biol Interact. 2015 Mar 5;229:26-35
pubmed: 25637687
J Pharm Pharmacol. 2017 Nov;69(11):1419-1427
pubmed: 28675431
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
DNA Cell Biol. 2013 Feb;32(2):50-7
pubmed: 23347444
Biochem Pharmacol. 2013 Oct 1;86(7):872-87
pubmed: 23933386
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Iran J Basic Med Sci. 2013 Jan;16(1):27-38
pubmed: 23638290
J Hematol Oncol. 2017 Feb 1;10(1):36
pubmed: 28143526
Food Chem Toxicol. 2014 Feb;64:65-80
pubmed: 24275090
Sci Rep. 2018 Oct 9;8(1):15029
pubmed: 30301907
J Nat Med. 2016 Jan;70(1):62-74
pubmed: 26439477
Int J Clin Oncol. 2019 Jun;24(6):614-623
pubmed: 30919257
Urol Oncol. 2019 May;37(5):299.e7-299.e18
pubmed: 30660494
BMC Genomics. 2006 Oct 09;7:252
pubmed: 17029630
Phytomedicine. 2018 Apr 1;43:21-27
pubmed: 29747750
Head Neck. 2006 Sep;28(9):813-8
pubmed: 16637057
Nucleic Acids Res. 2005 Nov 10;33(20):e175
pubmed: 16284200
Mol Cell Endocrinol. 2004 Feb 27;215(1-2):63-72
pubmed: 15026176
Asian Pac J Cancer Prev. 2010;11(3):675-9
pubmed: 21039035
BMC Cancer. 2015 Jan 15;15:5
pubmed: 25588809
Pak J Pharm Sci. 2017 Sep;30(5):1629-1634
pubmed: 29084683
Pathology. 2018 Apr;50(3):293-297
pubmed: 29452694
Lancet Oncol. 2008 Mar;9(3):279-87
pubmed: 18308253

Auteurs

Yushuang Luo (Y)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Pengjie Yu (P)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Junhui Zhao (J)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Qijing Guo (Q)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Baohua Fan (B)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Yinzhuo Diao (Y)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Yulong Jin (Y)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Chengwu Zhang (C)

Department of Oncology, Affiliated Hospital of Qinghai University Xining, Qinghai, China.

Classifications MeSH